These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19517471)

  • 1. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas.
    Robledo C; García JL; Caballero D; Conde E; Arranz R; Flores T; Grande C; Rodríguez J; García E; Sáez AI; González M; Gutiérrez NC; Piris MA; Hernández JM;
    Cancer; 2009 Aug; 115(16):3728-37. PubMed ID: 19517471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.
    Jardin F; Ruminy P; Kerckaert JP; Parmentier F; Picquenot JM; Quief S; Villenet C; Buchonnet G; Tosi M; Frebourg T; Bastard C; Tilly H
    Haematologica; 2008 Apr; 93(4):543-50. PubMed ID: 18287131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
    Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
    Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
    Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
    J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
    Tagawa H
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
    Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
    Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
    Vranovsky A; Ladicka M; Lakota J
    Neoplasma; 2008; 55(2):107-12. PubMed ID: 18652043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
    Scandurra M; Mian M; Greiner TC; Rancoita PM; De Campos CP; Chan WC; Vose JM; Chigrinova E; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Montes-Moreno S; Piris MA; Facchetti F; Tucci A; Nomdedeu JF; Lazure T; Lambotte O; Uccella S; Pinotti G; Pruneri G; Martinelli G; Young KH; Tibiletti MG; Rinaldi A; Zucca E; Kwee I; Bertoni F
    Br J Haematol; 2010 Nov; 151(3):221-31. PubMed ID: 20813005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
    Zinzani PL; Broccoli A; Stefoni V; Musuraca G; Abruzzese E; De Renzo A; Cantonetti M; Bacci F; Baccarani M; Pileri SA
    Cancer; 2010 Dec; 116(24):5667-75. PubMed ID: 20737566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
    Tucci A; Ferrari S; Bottelli C; Borlenghi E; Drera M; Rossi G
    Cancer; 2009 Oct; 115(19):4547-53. PubMed ID: 19562776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated profiling of diffuse large B-cell lymphoma with 7q gain.
    Chigrinova E; Mian M; Shen Y; Greiner TC; Chan WC; Vose JM; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Tucci A; Facchetti F; Lazure T; Lambotte O; Montes-Moreno S; Piris MA; Zucca E; Kwee I; Bertoni F
    Br J Haematol; 2011 May; 153(4):499-503. PubMed ID: 21418177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C
    Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas.
    Beà S; Colomo L; López-Guillermo A; Salaverria I; Puig X; Pinyol M; Rives S; Montserrat E; Campo E
    J Clin Oncol; 2004 Sep; 22(17):3498-506. PubMed ID: 15337798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.